Shares of Mesoblast Ltd (MSB.AU) are soaring in Wednesday's intraday trading, climbing 5.24% following a bullish analyst update. The surge comes after Piper Sandler, a prominent investment bank, significantly raised its target price for the Australian biotechnology company.

Piper Sandler has increased its target price for Mesoblast from $24 to $35, representing a substantial 45.8% upward revision. This new target suggests considerable upside potential from the stock's current trading levels, sparking investor interest and driving the share price higher.

The raised target price often indicates an analyst's increased confidence in a company's future prospects. For Mesoblast, a company focused on developing and commercializing allogeneic cellular medicines, this positive outlook could be based on factors such as promising clinical trial results, potential regulatory approvals, or improved financial forecasts. Investors are likely interpreting this upgrade as a signal of Mesoblast's strengthening position in the competitive biotechnology sector.